Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

A likely recovery

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2015 | 03:06pm

Technical indicators currently tested are likely to allow AbbVie shares to rally again.

The research-based biopharmaceutical company displays high-quality fundamentals. It has an attractive valuation with a P/E ratio of 13.3x for 2015 and an appealing yield of 3.43%. Reuters estimates shows its outstanding growth potential and its rising profitability: EPS should increase by 290% in 2015.

Technically, the stock is in an oversold situation. Prices came back on their lower ascendant trendline on both daily and weekly data. The stock seem to start a technical rebound at this level. Thus, the stock could find new energy and rise towards the next USD 61.7 resistance.

Therefore, it seems opportune to take a long position on AbbVie and target in a first place the USD 61.7 resistance. Traders should not insist below the USD 55.5 support and a stop-loss order should be placed under this threshold.


Anas Boumedian
© Zonebourse.com 2015
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 21,01
P/E ratio 2018 16,57
EV / Sales 2017 6,51x
EV / Sales 2018 5,76x
Capitalization 155 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBVIE
Duration : Period : Day
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Duration : Period : Week
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders